Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | MDM4 | O15151 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 2/20 | 0.37 |
| ▸ | FABP7 | O15540 | 1/20 | 0.37 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.37 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15947621 | 0.90 | KMT2A (0.48) | KMT2AEPHX2MDM4TP53CASP3 | |
| SCHEMBL30242843 | 0.85 | KMT2A (0.60) | KMT2AEPHX2MDM4TP53CASP3 | |
| SCHEMBL3727338 | 0.85 | KMT2A (0.60) | KMT2AEPHX2MDM4TP53CASP3 | |
| SCHEMBL29400248 | 0.84 | KMT2A (0.50) | KMT2AEPHX2MDM4TP53CASP3 | |
| SCHEMBL31309889 | 0.84 | KMT2A (0.50) | KMT2AEPHX2MDM4TP53CASP3 | |
| SCHEMBL10661146 | 0.84 | KMT2A (0.50) | KMT2AEPHX2MDM4TP53CASP3 | |
| SCHEMBL30905361 | 0.82 | KMT2A (0.56) | KMT2AEPHX2MDM4TP53CASP3 | |
| SCHEMBL31603929 | 0.82 | KMT2A (0.56) | KMT2AEPHX2MDM4TP53CASP3 | |
| SCHEMBL15692103 | 0.82 | KMT2A (0.56) | KMT2AEPHX2MDM4TP53CASP3 | |
| SCHEMBL13930525 | 0.81 | KMT2A (0.47) | KMT2AEPHX2MDM4TP53DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113348181-A | DC-SIGN antibody conjugates comprising a STING agonist | 诺华股份有限公司 | 2021-09-03 | — | — | CN | disclosed |
| US-20100221749-A1 | THREE-FUNCTIONAL PSEUDO-PEPTIDIC REAGENT, AND USES AND APPLICATIONS THEREOF | UNIVERSITE DE ROUEN | 2010-09-02 | — | — | US | disclosed |
| US-20100221749-A1 | THREE-FUNCTIONAL PSEUDO-PEPTIDIC REAGENT, AND USES AND APPLICATIONS THEREOF | UNIVERSITE DE ROUEN | 2010-09-02 | — | — | US | disclosed |
| WO-2009043986-A1 | THREE-FUNCTIONAL PSEUDO-PEPTIDIC REAGENT, AND USES AND APPLICATIONS THEREOF | UNIVERSITE DE ROUEN (FR) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100221749-A1 | THREE-FUNCTIONAL PSEUDO-PEPTIDIC REAGENT, AND USES AND APPLICATIONS THEREOF | DNPEP, PEPD, LNPEP | KMT2A 3483/4885EPHX2 1352/4885MDM4 3481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.